KOSPI 8,400line regained, with biotech stocks such as Chong Kun Dang and HanAll gaining
The KOSPI 8,400reclaimed the line and 2posted gains in the percent range. Chong Kun Dang defended its earnings thanks to the Wegovy effect, while a target price for HanAll Biopharma, citing new-drug results, was set at 13in ten-thousand-won units.
Get free 종근당 email updates.
Bullstory sends one daily email when new analysis or important company news is available.
The KOSPI 8,400reclaimed the line, with the index 2rising in the percent range. Across the market, biotech and healthcare-related stocks made notable moves. Trading volume in the sector increased during the day’s trading.
Chong Kun Dang held up its earnings thanks to the Wegovy effect. The company said new drugs were driving a revaluation of its share price. The announcement drew investors’ attention.
HanAll Biopharma announced a world-first achievement, and a target price of 13in ten-thousand-won units was indicated in connection with it. The company disclosed the results of its new drug. The news was reflected in trading.
InBody has launched a collaboration on AI-based body composition management in partnership with Naver Healthcare. The two companies announced the scope of service integration and data use. The collaboration aims to expand healthcare service features.
MEZOO received manufacturing approval for a next-generation product, and its share price surged following the news. The company disclosed that it had obtained manufacturing approval. The disclosure stated that the approved product could affect future results.
Daewoong, Seers, and TR announced the joint development of a next-generation smart hospital ward solution. The three companies disclosed details of their technical cooperation and product commercialization schedule. The disclosure attracted interest from companies involved in hospital solutions.